Michael J. Mitten

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Saul H. Rosenberg, Stephen W. Fesik, C. Tse, 2010, Cancer Chemotherapy and Pharmacology.

The Volume of Three-Dimensional Cultures of Cancer Cells InVitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors

Catarina Brito, Xin Lu, Kedar S Vaidya, 2017, Neoplasia.

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Dolores Diaz, Jun Chen, Deepak Sampath, 2015, Science Translational Medicine.